FoodPharmer Vs Bournvita: Disparagement Not Allowed But No Embargo On Stating Facts, Says Delhi HC
The Delhi High Court clarified on Wednesday that its previous directive to Revant Himatsingka, also known as the FoodPharmer, to stop making disparaging videos about well-known household beverages like Bournvita and Tang was only limited to preventing disparagement.
A single-judge bench of Justice Amit Bansal underscored that there was no injunction against stating facts, and that FoodPharmer could continue making factual statements as a part of his videos or posts.
Have not stopped you from speaking about it, just don't disparage.Delhi High Court
In response, FoodPharmer's counsel said that this was a case where the threshold of disparagement would have to be tested ultimately, and its outcome would delineate the freedom of expression to speak about such things.
Multinational giant Mondelez International initiated the case against FoodPharmer after his viral videos where he attempts to decode the real nutritional facts behind the so-called "health drinks".
On Oct. 15, the high court passed an interim order, directing FoodPharmer to stop posting disparaging posts or videos pertaining to Tang or Bournvita. Mondelez is the parent company of household products such as Bournvita, Tang, Cadbury Oreo, and the like.
Last year, FoodPharmer made a video calling out Bournvita regarding its deceptive marketing tactics, whereby the brand promises to make its consumers taller, sharper, and stronger. However, FoodPharmer showed the entire nation that the beverage mix is essentially 50% sugar.
For this, he simply referred to the nutritional information provided on the backside of the packaging. This video received overwhelming support from all sections of society, including the government, which forced Mondelez to slash Bournvita's sugar content by 15%.
In its aftermath, FoodPharmer became India's poster boy for inculcating healthy habits in its everyday life and has spearheaded the revolution of looking at the nutritional information before buying any packaged product from the market.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.